Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis

2011 ◽  
Vol 31 (7) ◽  
pp. 1603-1610 ◽  
Author(s):  
A. Burkett ◽  
K. L. Vandemheen ◽  
T. Giesbrecht-Lewis ◽  
K. Ramotar ◽  
W. Ferris ◽  
...  
Thorax ◽  
2011 ◽  
Vol 66 (8) ◽  
pp. 680-685 ◽  
Author(s):  
K. de Boer ◽  
K. L. Vandemheen ◽  
E. Tullis ◽  
S. Doucette ◽  
D. Fergusson ◽  
...  

2020 ◽  
Author(s):  
Paul Briaud ◽  
Sylvère Bastien ◽  
Laura Camus ◽  
Marie Boyadjian ◽  
Philippe Reix ◽  
...  

AbstractStaphylococcus aureus (SA) is the major colonizer of the lung of cystic fibrosis (CF) patient during childhood and adolescence. As patient aged, the prevalence of SA decreases and Pseudomonas aeruginosa (PA) becomes the major pathogen infecting adult lungs. Nonetheless, SA remains significant and patients harbouring both SA and PA are frequently found in worldwide cohort. Impact of coinfection remains controversial. Furthermore, co-infecting isolates may compete or coexist. The aim of this study was to analyse if co-infection and coexistence of SA and PA could lead to worse clinical outcomes. The clinical and bacteriological data of 212 Lyon CF patients were collected retrospectively, and patients were ranked into three groups, SA only (n=112), PA only (n=48) or SA plus PA (n=52). In addition, SA and PA isolates from co-infecting patients were tested in vitro to define their interaction profile. Sixty five percent (n=34) of SA/PA pairs coexist. Using univariate and multivariate analysis, we confirm that SA patients have a clinical condition less severe than others, and PA induce a poor outcome independently of the presence of SA. FEV1 is lower in patients infected by competition strain pairs than in those infected by coexisting strain pairs compared to SA mono-infection. Coexistence between SA and PA may be an important step in the natural history of lung bacterial colonization within CF patients.


2020 ◽  
pp. AAC.02327-20 ◽  
Author(s):  
Claire L Keating ◽  
Jonathan B Zuckerman ◽  
Pradeep K Singh ◽  
Matthew McKevitt ◽  
Oksana Gurtovaya ◽  
...  

Rationale: Approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect susceptibility profiles of Pseudomonas aeruginosa (PA) isolates from cystic fibrosis (CF) patients.Objective: This 5-year, prospective, observational study tracked susceptibility changes and clinical outcomes in CF patients in the United States with chronic PA infection.Methods: Sputum cultures were collected annually (2011-2016). The primary study endpoint was the proportion of subjects whose least susceptible PA isolate had an aztreonam minimum inhibitory concentration (MIC) that was >8 μg/mL (parenteral breakpoint) and increased ≥4-fold compared with the least susceptible isolate from the previous year. Annualized data for pulmonary exacerbations, hospitalizations, and FEV1% predicted were obtained from the CF Foundation Patient Registry and compared between subjects meeting/not meeting the primary endpoint.Results: 510 subjects were enrolled; 334 (65%) completed the study. A consistent proportion of evaluable subjects (13-22%) met the primary endpoint each year; and AZLI use during the previous 12 months was not associated with meeting the primary endpoint. While the annual decline in lung function was comparable for subjects meeting/not meeting the primary endpoint, more pulmonary exacerbations and hospitalizations were experienced by those who met it.Conclusions: Aztreonam susceptibility of PA remained consistent during the 5-year study. The relationship between PA isolate susceptibilities and clinical outcomes is complex; reduced susceptibility was not associated with accelerated decline in lung function, but was associated with more exacerbations and hospitalizations, likely reflecting increased overall antibiotic exposure.


JAMA ◽  
2010 ◽  
Vol 304 (19) ◽  
pp. 2145 ◽  
Author(s):  
Shawn D. Aaron ◽  
Katherine L. Vandemheen ◽  
Karam Ramotar ◽  
Tracy Giesbrecht-Lewis ◽  
Elizabeth Tullis ◽  
...  

2016 ◽  
Vol 15 (3) ◽  
pp. 392-399 ◽  
Author(s):  
Julia Pritchard ◽  
Mitesh V. Thakrar ◽  
Ranjani Somayaji ◽  
Michael G. Surette ◽  
Harvey R. Rabin ◽  
...  

2001 ◽  
Vol 69 (2) ◽  
pp. 1185-1188 ◽  
Author(s):  
Joel Moss ◽  
Mary E. Ehrmantraut ◽  
Bruce D. Banwart ◽  
Dara W. Frank ◽  
Joseph T. Barbieri

ABSTRACT Expression of type III proteins of Pseudomonas aeruginosa in patients with cystic fibrosis (CF) was investigated by measuring the immune response against components of the type III pathway. Twenty-three of the 33 sera contained antibodies against PcrV, a protein involved in translocation of type III cytotoxins into eukaryotic cells, and 11 of 33 had antibodies against ExoS, while most CF sera contained antibodies against PopB and PopD, components of the type III apparatus. These data indicate that P. aeruginosacommonly expresses components of the type III translocation apparatus in adult CF patients.


2010 ◽  
Vol 67 (3) ◽  
pp. 127-132 ◽  
Author(s):  
J. R. Rao ◽  
D. Nelson ◽  
J. E. Moore ◽  
B. C. Millar ◽  
C. E. Goldsmith ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document